Gilead Sciences, Inc. stands to further entrench its CAR-T therapy Yescarta (axicabtagene ciloleucel) with results showing superior efficacy to standard of care therapy in second-line large B-cell lymphoma (LBCL) disease, despite facing potential competition from a newer entrant, Bristol Myers Squibb Company’s Breyanzi (lisocabtagene maraleucel).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?